Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

DDW 2015: Sofosbuvir/ Ledipasvir Cures Most Hepatitis C Patients with Cirrhosis

Sofosbuvir and ledipasvir -- the drugs in Harvoni -- are well-tolerated and highly effective for genotype 1 chronic hepatitis C patients with compensated cirrhosis, producing an overall cure rate of 96%, according to a pooled analysis of more than 500 participants in Phase 2 and 3 studies, according to a presentation at Digestive Disease Week 2015 this month in Washington, DC.

alt

Read more:

DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients

Nearly all HIV/HCV coinfected patients treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza) achieved sustained virological response, but the cure rate fell to 76% for those treated for only 8 weeks, according to results from the ALLY-2 trial presented at Digestive Disease Week 2015 this month in Washington, DC.

alt

Read more:

EASL 2015: Sofosbuvir/ Ledipasvir Cures More Than 90% of People with Hepatitis C Genotypes 4 and 5

An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.

alt

Read more:

Daclatasvir, Asunaprevir, and Beclabuvir Shows High Cure Rates for People with Genotype 1 Hepatitis C

A twice-daily fixed-dose coformulation of daclatasvir, asunaprevir, and beclabuvir taken for 12 weeks cured 91% of genotype 1 chronic hepatitis C patients without liver cirrhosis, and even higher sustained response rates were obtained for people with cirrhosis when ribavirin was added, according to findings from the Phase 3 UNITY studies published in the May 5 issue of JAMA.

alt

Read more:

EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C

A 12-week course of the combination of grazoprevir and elbasvir cured 95% of previously untreated people with hepatitis C virus gentoypes 1, 4, or 6, according to results of the C-EDGE trial presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. However, the study also showed that people with higher baseline HCV viral load and genotype 1a may have a poorer response to this combination, particularly if they have naturally occurring HCV variants that are less sensitive to drugs from the NS5A inhibitor class.

alt

Read more: